Business Context and Reporting Period
Cormedix Inc. filed this Form 8-K on April 28, 2017, reporting the entry into a material definitive agreement. The company, incorporated in Delaware, is based in Bedminster, NJ. The filing details an underwritten public offering that closed on May 3, 2017.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $14.0 million from the sale of shares (before underwriting discounts and expenses).
- Offering Price: $0.75 per share of common stock and related warrants.
- Shares Issued: A total of 18,619,301 shares of common stock were sold and issued after the full exercise of the underwriters' option.
- Warrants Issued:
- Series A Warrants: 13,964,475 shares at an exercise price of $1.05 (5-year term).
- Series B Warrants: 13,964,475 shares at an exercise price of $0.75 (13-month term).
- Underwriter Warrants: 1,117,157 shares at an exercise price of $0.9375 (5-year term).
- Underwriting Compensation: 6.0% commission of gross proceeds plus the issuance of underwriter warrants.
Material Changes and Conditions
The primary material change is the significant capital raise and the associated dilution from the issuance of common stock and warrants. A critical condition precedent exists regarding the exercisability of the warrants:
- Authorized Share Limitation: The company currently lacks sufficient authorized shares to cover the warrants.
- Required Action: Stockholder approval of a Charter Amendment to increase authorized shares to 200,000,000 is required at the annual meeting on June 6, 2017.
- Consequence of Failure: If the amendment is not approved, the warrants will not be exercisable and may have no value. Until approval, the company cannot sell any securities.
Outlook, Risks, and Contingencies
The filing highlights a specific contingency risk tied to the June 6, 2017, annual meeting. The value of the Series A and Series B warrants is contingent upon stockholder approval of the Charter Amendment. Without this approval, the warrants may become worthless. The offering was conducted pursuant to a shelf registration statement on Form S-3.
Investor Verification Checklist
- Verify the outcome of the stockholder vote on the Charter Amendment at the June 6, 2017, annual meeting.
- Confirm the net proceeds received after deducting the 6.0% underwriting commission and offering expenses.
- Monitor the "Exercisable Date" announcement via a future Form 8-K to determine when warrants can be exercised.
- Review the full underwriting agreement (Exhibit 1.1) for specific indemnification obligations and termination provisions.